March 6, 2019
Zealand Pharma doses first patients testing its drug for congenital hyperinsulinism
Zealand Pharma has doesd its first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism, the company said Wednesday.